Thymosin Alpha-1
zadaxinthymalfasinta-1talpha 1
Approved immune peptide (Zadaxin). Clinical history for hep B/C; protocol + tracking guidance.
- Half-life
- 2 h
- Out of system
- ~10 h
- Route
- Subcutaneous
- Level
- Intermediate
Short-acting — protocols usually dose daily. After the last dose, roughly 97% has cleared in ~10 h (five half-lives) — the window that matters for washouts, bloodwork and surgery.
What Thymosin Alpha-1 is used for
- Approved immune peptide (Zadaxin) — modulates T-cell immunity
- Clinical history for hepatitis B/C and as a vaccine adjuvant
How it's typically used
Clinical range: ~1.6 mg subcutaneous twice weekly.
What to watch for
- Approved abroad, not by the US FDA for general use
- Injection-site reactions possible
- Discuss with a clinician if immunocompromised
About Other research compounds
- What they are
- Nootropics, metabolic agents, and research compounds that don't fit the other classes.
- How they're run
- Route and schedule vary widely — check the individual entry.
- What to watch
- This is the least-characterised corner of the atlas. Read the full guide, and treat anything without published human data as exactly that.
Full guide
Thymosin Alpha-1 (TA1): A Tracking Guide for an Approved Immune Peptide
What Thymosin Alpha-1 is, its approval history as Zadaxin, typical protocol shapes, and how to track an immune-focused cycle.
Other other research compounds
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.